Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral therapy in developing countries. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
184
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Yunnan provincial infectious disease hosipital
Kunming, Yunnan, China
Percentage of patients with HIV RNA<50 Copies/ml
Time frame: 48 weeks
Adverse events
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.